FMP

FMP

Enter

BCDAW - BioCardia, Inc.

Financial Summary of BioCardia, Inc.(BCDAW), BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular

photo-url-https://financialmodelingprep.com/image-stock/BCDAW.png

BioCardia, Inc.

BCDAW

NASDAQ

Inactive Equity

BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

0.019 USD

-0.0078 (-41.05%)

About

ceo

Dr. Peter A. Altman Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.biocardia.com

exchange

NASDAQ

Description

BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that deliver...

CIK

0000925741

ISIN

US09060U1198

CUSIP

09060U119

Address

320 Soquel Way

Phone

650 226 0120

Country

US

Employee

16

IPO Date

Aug 2, 2019

Summary

CIK

0000925741

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

09060U119

ISIN

US09060U1198

Country

US

Price

0.02

Beta

1.49

Volume Avg.

0

Market Cap

9.67M

Shares

-

52-Week

0.019-0.019

DCF

-0.25

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.01

P/B

-

Website

https://www.biocardia.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest BCDAW News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep